Abemaciclib, a CDK4 and 6 inhibitor with unique pharmacological properties for breast cancer therapy.

JOURNAL ARTICLE published 20 May 2021 in Journal of Clinical Oncology

Authors: Raquel Torres-Guzmán | Maria Patricia Ganado | Cecila Mur Pérez | Carlos Marugán | Carmen Baquero | Yanzhu Yang | Jian Du | Alfonso de Dios | Oscar Puig | Maria Jose Lallena